Personalized Models for Cancer Research
Part of paid clinical trials in New York, New York.
- Sponsor
- New York Stem Cell Foundation Research Institute
- Study ID
- NCT06350539
- Status
- Recruiting
Conditions
- Solid Tumor, Adult
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Biological Sample Collection — OTHERExcess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
Study Details
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.
Key Dates
- Start date
- Feb 15, 2024
- Status verified
- Jul 2024
- Primary completion
- Feb 15, 2034
- Completion
- Feb 15, 2034
Study Design
- Enrollment
- 500 participants (estimated)
Arms
- Arm: Affected SubjectsSubjects in this group will have a solid tumor cancer diagnosis.
- Arm: Healthy ControlSubjects in this group will serve as healthy controls.
Primary Outcome Measure
Implement organoid culture technologies. [ Time Frame: Baseline ]
Central Contacts
- Clinical Research Office212-927-1801
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| New York Stem Cell Foundation Research Institute | New York | New York | 10019 | Laura Andres-Martin, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site
Related Studies
- Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With SarcomaPHASE1/PHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · St. Petersburg, Florida
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsPHASE1/PHASE2 · Recruiting · Immatics US, Inc. · Stanford, California
- Psychotherapy Intervention for Latinos With Advanced CancerRecruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabPHASE1/PHASE2 · Recruiting · Linnaeus Therapeutics, Inc. · Los Angeles, California